Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raxibacumab in symptomatic inhalational anthrax
NCT02177721Phase 4Not yet recruiting
- Sponsor
- Emergent BioSolutions
- Start
- Jan 2027
- Primary completion
- May 2035
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of Raxibacumab in inhalational anthrax, sponsored by Emergent BioSolutions. Primary endpoint: Clinical Benefit of Raxibacumab at 29 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Raxibacumab
03
Conditions
inhalational anthrax
Beyond the preview
Go deeper on NCT02177721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177721.